JP7542799B2 - 眼組織の線維化抑制用組成物 - Google Patents

眼組織の線維化抑制用組成物 Download PDF

Info

Publication number
JP7542799B2
JP7542799B2 JP2020529077A JP2020529077A JP7542799B2 JP 7542799 B2 JP7542799 B2 JP 7542799B2 JP 2020529077 A JP2020529077 A JP 2020529077A JP 2020529077 A JP2020529077 A JP 2020529077A JP 7542799 B2 JP7542799 B2 JP 7542799B2
Authority
JP
Japan
Prior art keywords
obp
fibrosis
tissue
surgery
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020529077A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020009248A1 (ja
JPWO2020009248A5 (enExample
Inventor
盛夫 上野
千恵 外園
淳爾 羽室
茂 木下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KYOTO PREFECTURAL UNIVERSITY OF MEDICINE
Oncolys Biopharma Inc
Original Assignee
KYOTO PREFECTURAL UNIVERSITY OF MEDICINE
Oncolys Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KYOTO PREFECTURAL UNIVERSITY OF MEDICINE, Oncolys Biopharma Inc filed Critical KYOTO PREFECTURAL UNIVERSITY OF MEDICINE
Publication of JPWO2020009248A1 publication Critical patent/JPWO2020009248A1/ja
Publication of JPWO2020009248A5 publication Critical patent/JPWO2020009248A5/ja
Priority to JP2024131200A priority Critical patent/JP7763438B2/ja
Application granted granted Critical
Publication of JP7542799B2 publication Critical patent/JP7542799B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020529077A 2018-07-04 2019-07-03 眼組織の線維化抑制用組成物 Active JP7542799B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024131200A JP7763438B2 (ja) 2018-07-04 2024-08-07 眼組織の線維化抑制用組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018127738 2018-07-04
JP2018127738 2018-07-04
PCT/JP2019/027233 WO2020009248A1 (ja) 2018-07-04 2019-07-03 眼組織の線維化抑制用組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024131200A Division JP7763438B2 (ja) 2018-07-04 2024-08-07 眼組織の線維化抑制用組成物

Publications (3)

Publication Number Publication Date
JPWO2020009248A1 JPWO2020009248A1 (ja) 2021-08-12
JPWO2020009248A5 JPWO2020009248A5 (enExample) 2022-08-09
JP7542799B2 true JP7542799B2 (ja) 2024-09-02

Family

ID=69059196

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020529077A Active JP7542799B2 (ja) 2018-07-04 2019-07-03 眼組織の線維化抑制用組成物
JP2024131200A Active JP7763438B2 (ja) 2018-07-04 2024-08-07 眼組織の線維化抑制用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024131200A Active JP7763438B2 (ja) 2018-07-04 2024-08-07 眼組織の線維化抑制用組成物

Country Status (2)

Country Link
JP (2) JP7542799B2 (enExample)
WO (1) WO2020009248A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024150780A (ja) * 2018-07-04 2024-10-23 京都府公立大学法人 眼組織の線維化抑制用組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113057142B (zh) * 2021-03-30 2022-12-09 四川大学华西医院 一种视网膜内和/或视网膜下纤维化动物模型的构建方法
AU2023249281A1 (en) * 2022-04-08 2024-10-17 University Of North Texas Health Science Center At Fort Worth Treatment for ocular fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
EA201391012A1 (ru) * 2011-01-06 2014-01-30 Глэксо Груп Лимитед Лиганды, связывающиеся с рецепторами tgf-бета типа ii
ES2917222T3 (es) * 2011-12-28 2022-07-07 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
US11730722B2 (en) * 2013-07-30 2023-08-22 Kyoto Prefectural Public University Corporation Corneal endothelium ECM therapeutic medicaments
JP2016113379A (ja) * 2014-12-11 2016-06-23 京都府公立大学法人 分子標的薬を用いる腫瘍治療及び予防用併用薬
WO2020009248A1 (ja) 2018-07-04 2020-01-09 京都府公立大学法人 眼組織の線維化抑制用組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IOVS，2013年，Vol.54,No.15，360

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024150780A (ja) * 2018-07-04 2024-10-23 京都府公立大学法人 眼組織の線維化抑制用組成物
JP7763438B2 (ja) 2018-07-04 2025-11-04 京都府公立大学法人 眼組織の線維化抑制用組成物

Also Published As

Publication number Publication date
JP2024150780A (ja) 2024-10-23
WO2020009248A1 (ja) 2020-01-09
JP7763438B2 (ja) 2025-11-04
JPWO2020009248A1 (ja) 2021-08-12

Similar Documents

Publication Publication Date Title
JP7763438B2 (ja) 眼組織の線維化抑制用組成物
AU2023251388B2 (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
Baudouin Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma
KR102496234B1 (ko) 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법
US11865123B2 (en) Methods of inhibiting pathological angiogenesis
CN109996814B (zh) 多激酶抑制剂及在眼部纤维化中的用途
JP2012229257A (ja) 治療用組成物および方法
TW201440774A (zh) 眼底疾患治療劑
Mietz et al. Long-term intraocular toxic effects of topical mitomycin C in rabbits
Liu et al. A novel rat model of ocular hypertension by a single intracameral injection of cross‐linked hyaluronic acid hydrogel (Healaflow®)
Ma et al. Latanoprost eye drops induce conjunctival lymphatic vessel development
JP7580123B2 (ja) 血管新生関連疾患の予防又は治療用医薬組成物
EP4574146A1 (en) Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
RU2815482C2 (ru) Лечение глазных болезней типа дегенерации желтого пятна, глаукомы и диабетической ретинопатии с помощью лекарственных средств, устраняющих стареющие клетки
CN117224546A (zh) Cz415在制备降眼压药物上的应用
US20150284393A1 (en) Methods for treating eye disorders
Plummer Chronic Diseases of the Eye and Adnexa
Gowtham et al. 6 Newer Drugs in Glaucoma
HK40032714A (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
HK40000005B (zh) 使用尼达尼布改善青光眼手术成功情况的组合物和方法

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20210413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240807

R150 Certificate of patent or registration of utility model

Ref document number: 7542799

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150